Clinical Trials
9 trialsNCT04666272 2026-02-19
Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection
Novartis
Active not recruiting
NCT04961619 2025-12-12
LEAD Melanoma
Novartis
Completed
NCT07092670 2025-09-05
MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.
Intergruppo Melanoma Italiano
Recruiting
NCT03944356 2025-03-12
Combi-EU
EuMelaReg gGmbH
Completed
NCT05260684 2025-03-06
OCEANMIST
Pfizer
Completed
NCT04547946 2023-05-30
Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)
Novartis
Completed
NCT05714371 2023-02-06
Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma
Novartis
Completed
NCT05171374 2022-06-01
RATIONALE
MelanomaPRO, Russia
Unknown
NCT02439411 2019-12-02
DEIS
Grupo Español Multidisciplinar de Melanoma
Completed